Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
TrkA receptor inhibitor
DRUG CLASS:
TrkA receptor inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
larotrectinib (189)
entrectinib (178)
GW441756 (1)
KRC-108 (1)
DCC-2701 (0)
PBI-200 (0)
larotrectinib (189)
entrectinib (178)
GW441756 (1)
KRC-108 (1)
DCC-2701 (0)
PBI-200 (0)
›
Associations
(369)
News
Trials
VERI cancer hierarchy
Reset Filters
ROS1 fusion
Non Small Cell Lung Cancer
ROS1 fusion
Non Small Cell Lung Cancer
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
NTRK3 fusion
Sarcoma
NTRK3 fusion
Sarcoma
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
NTRK2 fusion
Sarcoma
NTRK2 fusion
Sarcoma
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
NTRK1 fusion
Sarcoma
NTRK1 fusion
Sarcoma
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
NTRK3 fusion
Solid Tumor
NTRK3 fusion
Solid Tumor
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
NTRK3 fusion
Solid Tumor
NTRK3 fusion
Solid Tumor
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
NTRK2 fusion
Solid Tumor
NTRK2 fusion
Solid Tumor
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
No biomarker
Solid Tumor
No biomarker
Solid Tumor
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
NTRK1 fusion
Solid Tumor
NTRK1 fusion
Solid Tumor
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
NTRK2 fusion
Solid Tumor
NTRK2 fusion
Solid Tumor
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
NTRK1 fusion
Solid Tumor
NTRK1 fusion
Solid Tumor
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
No biomarker
Solid Tumor
No biomarker
Solid Tumor
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK3 fusion
Small Intestinal Carcinoma
NTRK3 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Small Intestinal Carcinoma
NTRK1 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Small Intestinal Carcinoma
NTRK2 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Soft Tissue Sarcoma
NTRK3 fusion
Soft Tissue Sarcoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK3 fusion
Pancreatic Adenocarcinoma
NTRK3 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Pancreatic Adenocarcinoma
NTRK2 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Pancreatic Adenocarcinoma
NTRK1 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Gastrointestinal Stromal Tumor
NTRK2 fusion
Gastrointestinal Stromal Tumor
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Breast Cancer
NTRK2 fusion
Breast Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK3 fusion
Breast Cancer
NTRK3 fusion
Breast Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Breast Cancer
NTRK1 fusion
Breast Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login